NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/14/2023
Back to search
Official data from USPTO
EARLI
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
51
Latest update
09/16/2023
Trademark type
Word
Nice classes
1, 5
Filing date
06/29/2018
Registration date
03/14/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/14/2023
Last transaction
09/16/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
01/18/2023
First use in commerce
01/18/2023
Drawing code
4
Owner type
03
Owner location
Mountain View, CA
Examiner
LEE, DOUGLAS
Law office
O20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Earli Inc.
Representatives
Connie L. Ellerbach FENWICK & WEST LLP
Technical classification
Nice Classes
Class 1Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Assaysrecombinant nucleic acid vectorstransfection agentsreagentsenzymesnucleotides for clinical or medical laboratoryscientificresearch purposes; diagnostic or screening assays or agentsreagentsenzymesnucleotides for clinical or medical laboratoryscientificresearchpurposes; reagents for medical and genetic research; chemical reagents and diagnostic preparations for clinical or medical laboratory use
Class 5
Pharmaceutical and veterinary preparations and products for the preventiondetectionlocalizationtreatment of cancerrespiratory diseasesliver diseases; Drug delivery agents in the form of compounds that facilitate the delivery of other pharmaceutical products into human and animal bodies; clinical medical diagnostic or therapeutic reagents and clinical diagnostic kits comprised of clinical medical diagnostic or therapeutic reagents; medical diagnostic or therapeutic reagents and medical diagnostic or therapeutic kits comprised of medical diagnostic or therapeutic reagents; reagents for medical use and medical diagnostics or therapeutics and screening kits comprised of reagents for medical diagnostics and screening use or therapeutics; reagents for use in testing for medical and medical diagnostic purposes; diagnostic and therapeutic preparations for medical purposesto detect and treat cancerrespiratory diseasesliver diseases; diagnostic or therapeutic assaysvectorsreagentsenzymesnucleotides for medical or clinical purposes; diagnostic or screening assaysreagentsenzymesnucleotides for medical diagnostic purposes and treatment purposesto detect and treat cancerrespiratory diseasesliver diseases; reagents for medical diagnostic purposes and treatment use; therapeutic agents for medical diagnostic purposes and treatmentviral vectors and non-viral transfection agents based on linear or branched polyethyleniminesnanoparticleslipophilic particlespeptidesmicellesdendrimershydrogelssynthetic or naturally derived exosomespolymeric compositionvirus-like particleswhich facilitate the delivery of pharmaceuticals or nucleic acids into human and animal bodies to detect and treat cancerrespiratory diseasesliver diseases
Publications
History of USPTO decisions and trademark events.
51 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
03/14/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
02/10/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
02/09/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
02/02/2023
IUAF
USE AMENDMENT FILED
01/31/2023
EISU
TEAS STATEMENT OF USE RECEIVED
01/31/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/18/2023
EX5G
SOU EXTENSION 5 GRANTED
01/17/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
01/04/2023
EXT5
SOU EXTENSION 5 FILED
12/15/2022
EEXT
SOU TEAS EXTENSION RECEIVED
12/15/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/16/2022
EX4G
SOU EXTENSION 4 GRANTED
06/14/2022
EXT4
SOU EXTENSION 4 FILED
06/14/2022
EEXT
SOU TEAS EXTENSION RECEIVED
06/14/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/18/2021
EX3G
SOU EXTENSION 3 GRANTED
12/16/2021
EXT3
SOU EXTENSION 3 FILED
12/16/2021
EEXT
SOU TEAS EXTENSION RECEIVED
12/16/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/18/2021
EX2G
SOU EXTENSION 2 GRANTED
05/14/2021
EXT2
SOU EXTENSION 2 FILED
05/14/2021
EEXT
SOU TEAS EXTENSION RECEIVED
05/14/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/24/2020
EX1G
SOU EXTENSION 1 GRANTED
12/22/2020
EXT1
SOU EXTENSION 1 FILED
12/22/2020
EEXT
SOU TEAS EXTENSION RECEIVED
12/22/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/14/2020
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
06/04/2020
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
02/13/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/14/2020
PUBO
PUBLISHED FOR OPPOSITION
01/14/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/25/2019
ALIE
ASSIGNED TO LIE
12/11/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/09/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/20/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/19/2019
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
11/19/2019
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
05/20/2019
GNFR
FINAL REFUSAL E-MAILED
05/20/2019
CNFR
FINAL REFUSAL WRITTEN
05/20/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/30/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/29/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/29/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/29/2018
GNRT
NON-FINAL ACTION E-MAILED
10/29/2018
CNRT
NON-FINAL ACTION WRITTEN
10/29/2018
DOCK
ASSIGNED TO EXAMINER
10/22/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/05/2018
NWAP
NEW APPLICATION ENTERED
07/03/2018
Continuous trademark protection
Get notified about every new filing that threatens EARLI or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.